Allena Pharmaceuticals Inc (NASDAQ:ALNA) Given Average Rating of “Buy” by Brokerages

Allena Pharmaceuticals Inc (NASDAQ:ALNA) has been given a consensus recommendation of “Buy” by the nine ratings firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $26.17.

ALNA has been the subject of several analyst reports. Roth Capital reduced their price objective on Allena Pharmaceuticals from $61.00 to $31.00 in a research report on Thursday, August 8th. ValuEngine upgraded shares of Allena Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Credit Suisse Group reiterated an “outperform” rating and issued a $26.00 price target on shares of Allena Pharmaceuticals in a research note on Monday, August 5th. Wedbush reiterated an “outperform” rating and issued a $36.00 price target on shares of Allena Pharmaceuticals in a research note on Monday, August 12th. Finally, Zacks Investment Research lowered shares of Allena Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 30th.

Shares of NASDAQ:ALNA traded down $0.02 during trading on Friday, hitting $4.35. 5,895 shares of the company traded hands, compared to its average volume of 44,782. The stock has a market capitalization of $105.62 million, a price-to-earnings ratio of -2.53 and a beta of 1.98. The business’s fifty day moving average is $4.35 and its 200-day moving average is $5.56. Allena Pharmaceuticals has a one year low of $3.62 and a one year high of $12.00. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.22.

Allena Pharmaceuticals (NASDAQ:ALNA) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.01). On average, analysts forecast that Allena Pharmaceuticals will post -1.98 EPS for the current year.

Institutional investors have recently added to or reduced their stakes in the company. Wedbush Securities Inc. acquired a new position in shares of Allena Pharmaceuticals during the 2nd quarter worth about $63,000. Jane Street Group LLC acquired a new position in shares of Allena Pharmaceuticals during the 2nd quarter worth about $116,000. Susquehanna International Group LLP acquired a new position in shares of Allena Pharmaceuticals during the 2nd quarter worth about $137,000. Deutsche Bank AG increased its stake in shares of Allena Pharmaceuticals by 8.2% during the 4th quarter. Deutsche Bank AG now owns 28,023 shares of the company’s stock worth $151,000 after purchasing an additional 2,118 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. increased its stake in shares of Allena Pharmaceuticals by 17.0% during the 2nd quarter. Jacobs Levy Equity Management Inc. now owns 41,587 shares of the company’s stock worth $169,000 after purchasing an additional 6,030 shares during the last quarter. Institutional investors own 67.89% of the company’s stock.

Allena Pharmaceuticals Company Profile

Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.

Featured Article: What is the Difference Between Common Shares and Convertible Shares?

Analyst Recommendations for Allena Pharmaceuticals (NASDAQ:ALNA)

Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.